506 related articles for article (PubMed ID: 21211857)
1. Renal glucose reabsorption inhibitors to treat diabetes.
Bailey CJ
Trends Pharmacol Sci; 2011 Feb; 32(2):63-71. PubMed ID: 21211857
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
Raskin P
Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
[TBL] [Abstract][Full Text] [Related]
3. SGLT2 inhibitors.
Dardi I; Kouvatsos T; Jabbour SA
Biochem Pharmacol; 2016 Feb; 101():27-39. PubMed ID: 26362302
[TBL] [Abstract][Full Text] [Related]
4. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).
Basile JN
J Diabetes Complications; 2013; 27(3):280-6. PubMed ID: 23375850
[TBL] [Abstract][Full Text] [Related]
5. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.
DeFronzo RA; Davidson JA; Del Prato S
Diabetes Obes Metab; 2012 Jan; 14(1):5-14. PubMed ID: 21955459
[TBL] [Abstract][Full Text] [Related]
6. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E; Ogasawara H
Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
Jabbour SA
Postgrad Med; 2014 Jan; 126(1):111-7. PubMed ID: 24393758
[TBL] [Abstract][Full Text] [Related]
8. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
Katz PM; Leiter LA
Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.
Ghosh RK; Ghosh SM; Chawla S; Jasdanwala SA
J Clin Pharmacol; 2012 Apr; 52(4):457-63. PubMed ID: 21543663
[TBL] [Abstract][Full Text] [Related]
10. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
Vallon V; Thomson SC
Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
[TBL] [Abstract][Full Text] [Related]
11. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
Washburn WN
J Med Chem; 2009 Apr; 52(7):1785-94. PubMed ID: 19243175
[No Abstract] [Full Text] [Related]
12. The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors.
Cangoz S; Chang YY; Chempakaseril SJ; Guduru RC; Huynh LM; John JS; John ST; Joseph ME; Judge R; Kimmey R; Kudratov K; Lee PJ; Madhani IC; Shim PJ; Singh S; Singh S; Ruchalski C; Raffa RB
J Clin Pharm Ther; 2013 Oct; 38(5):350-9. PubMed ID: 23909868
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.
Misra M
J Pharm Pharmacol; 2013 Mar; 65(3):317-27. PubMed ID: 23356840
[TBL] [Abstract][Full Text] [Related]
14. Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.
Washburn WN; Poucher SM
Expert Opin Investig Drugs; 2013 Apr; 22(4):463-86. PubMed ID: 23452053
[TBL] [Abstract][Full Text] [Related]
15. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition.
Rajeev SP; Cuthbertson DJ; Wilding JP
Diabetes Obes Metab; 2016 Feb; 18(2):125-34. PubMed ID: 26403227
[TBL] [Abstract][Full Text] [Related]
16. Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus.
Barnett AH
Postgrad Med; 2013 Sep; 125(5):92-100. PubMed ID: 24113667
[TBL] [Abstract][Full Text] [Related]
17. Beyond Glycosuria: Exploring the intrarenal effects of SGLT₋₂ inhibition in diabetes.
Thomas MC; Jandeleit-Dahm K; Bonnet F
Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S17-22. PubMed ID: 25554067
[TBL] [Abstract][Full Text] [Related]
18. Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Goodwin NC; Mabon R; Harrison BA; Shadoan MK; Almstead ZY; Xie Y; Healy J; Buhring LM; DaCosta CM; Bardenhagen J; Mseeh F; Liu Q; Nouraldeen A; Wilson AG; Kimball SD; Powell DR; Rawlins DB
J Med Chem; 2009 Oct; 52(20):6201-4. PubMed ID: 19785435
[TBL] [Abstract][Full Text] [Related]
19. Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.
Boyle LD; Wilding JP
Expert Opin Emerg Drugs; 2013 Sep; 18(3):375-91. PubMed ID: 23968378
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus.
Guthrie RM
Postgrad Med; 2013 May; 125(3):21-32. PubMed ID: 23748504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]